Project description DEENESFRITPL Innovative imaging platform for effective removal of cancerous tissue Effective removal of cancerous tissue by endoscopic surgery is challenging, partially because of the difficulty of differentiation of tissue types with current imaging technologies. Thericon in Germany is developing a real-time multispectral imaging platform with multiparametric images to assist in the effective removal of cancerous tissue and the reduction of cancer recurrence in patients. The company has developed a prototype device and completed initial validation in bladder cancer applications. The EU-funded rMSI project aims to complete clinical application studies, safety tests and certification of the final product in preparation for marketing. Show the project objective Hide the project objective Objective Cancer is the leading cause of death in the EU, with 2.7M diagnoses and 1.3M deaths in 2020. Effective removal of cancerous tissue through endoscopic surgery is challenging because of limited visual and absent tactile information, along the limitations of current imaging technologies, which make it difficult for surgeons to differentiate between different types of tissue. For this market, Thericon is developing an rMSI (real-time multispectral imaging) platform providing surgeons with multi-parametric images that help with effective removal of cancerous tissue and reduction of cancer recurrence in patients. The company has developed a prototype for its first product, named rMSI 2, and completed initial validation for bladder cancer applications. Thericon is asking for a 2.5M EIC grant and 5.5M equity funding to complete clinical application pilots, safety tests and CE certification for this product, getting it ready for market launch in 2024. Fields of science medical and health sciencesclinical medicineoncologybladder cancermedical and health sciencesclinical medicinesurgery Programme(s) HORIZON.3.1 - The European Innovation Council (EIC) Main Programme Topic(s) HORIZON-EIC-2022-ACCELERATOROPEN-01 - EIC Accelerator Open Call for proposal HORIZON-EIC-2022-ACCELERATOR-01 See other projects for this call Funding Scheme HORIZON-AG - HORIZON Action Grant Budget-Based Coordinator THERICON GMBH Net EU contribution € 2 500 000,00 Address Cubex41, universitatsmedizin mannheim theodor-kutzer-ufer 1-3 68167 Mannheim Germany See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Baden-Württemberg Karlsruhe Mannheim, Stadtkreis Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 1 592 151,25
